New hope for rare genetic blood cancer: interferon after transplant may cut relapse risk
NCT ID NCT07449286
First seen Mar 11, 2026 · Last updated May 13, 2026 · Updated 10 times
Summary
This study tests whether the drug interferon-α can help prevent cancer from coming back in people with a specific genetic mutation (TP53) in acute myeloid leukemia or myelodysplastic syndromes. All participants have already had a stem cell transplant and show no signs of cancer. The goal is to see if interferon can keep them cancer-free longer. About 100 people aged 12-65 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital, Peking University Institute of Hematology
Beijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.